March 15 Evening Listed Company Positive News Overview(with List)

Several listed companies in the Shanghai and Shenzhen markets released important announcements on the evening of March 15. Here is a summary of the positive news:

*ST Busen: Controlling shareholder plans to change control, trading halted from tomorrow

***ST Busen announced that on March 13, it received notice from its controlling shareholder, Fang Weitongchuang, that they are planning a transfer of control of the company. This may lead to a change in control. Currently, all parties are discussing and negotiating specific plans and agreements. The company’s stock will be suspended from trading starting March 16, with an expected suspension period of no more than two trading days.

Jingtou Development: Plans to transfer assets and liabilities related to real estate development to the controlling shareholder, potentially constituting a major asset restructuring**

Jingtou Development announced that it intends to transfer assets and liabilities related to its real estate development business to its controlling shareholder, Jingtou Company. The transfer will be paid in cash and will not involve issuing shares, nor will it affect the company’s equity structure or result in a change of control. This is expected to constitute a major asset restructuring.

Lutianhua: Net profit in 2025 to increase by 50.23% year-over-year**

Lutianhua disclosed its annual report, stating that in 2025, it achieved operating revenue of 4.495 billion yuan, a decrease of 11.34% year-over-year; net profit attributable to the parent was 31.78 million yuan, an increase of 50.23%; basic earnings per share were 0.02 yuan.

Qingniao Fire Protection: Plans to repurchase 2.5%-5% of company shares**

Qingniao Fire Protection announced that it plans to use its own funds and raised funds to repurchase shares through centralized bidding, at a price not exceeding 16.00 yuan per share. The repurchase will be no less than 2.5% of total shares, or 21,995,222 shares, and no more than 5%, or 43,990,443 shares. The repurchased shares will be used for employee stock ownership plans or equity incentives.

Zhefu Holding: Wins bid for 412 million yuan water turbine generator set and auxiliary equipment project**

Zhefu Holding announced that it recently received a bid-winning notice, confirming it as the successful bidder for the bidding project of water turbine generator sets and auxiliary equipment at the Changbo diversion hydropower station upstream of the Jinsha River, with a total bid amount of 412 million yuan, accounting for approximately 1.97% of the company’s 2024 revenue. With a delivery period of 27 months, this equates to an average of 0.73% of 2024 revenue per month. The company will produce components according to delivery schedules and recognize sales revenue accordingly, expected to increase sales revenue and net profit from 2027 to 2029.

Kede CNC: Co-establishes Excellence Innovation Center with Shanghai Flying Company**

On March 15, Kede CNC (688305) announced that it recently signed a revised agreement with Shanghai Aircraft Manufacturing Co., Ltd. (referred to as “Shanghai Flying”) to detail the core research and development focus of the previously signed “Co-Construction Agreement.” The two parties will jointly establish an Excellence Innovation Center, focusing on processing technology for typical aircraft parts, domestic equipment pilot verification, intelligent production line integration, and multi-domain collaborative “CNC workshop,” based on Kede CNC’s fully自主 high-end five-axis machine tools and CNC systems, and other domestically produced key core components.

Haisico: Innovative drug HSK55879 tablets approved for clinical trials**

Haisico announced that its subsidiary, Shanghai Haisico Shengnuo Pharmaceutical Technology Co., Ltd., recently received the “Drug Clinical Trial Approval Notice” from the National Medical Products Administration. After review, the IND applications for HSK55879 tablets for two indications, filed in December 2025, meet the requirements for drug registration, and clinical trials for both indications are approved. HSK55879 is a new generation oral small-molecule agonist developed independently by the company, with independent intellectual property rights, intended for treating metabolic system diseases.

Warner Pharmaceutical: Subsidiary passes FDA on-site inspection**

Warner Pharmaceutical announced that its wholly owned subsidiary, Hunan Warner Big Pharma Co., Ltd. (“Chiral Drug Company”), underwent a pre-approval inspection by the U.S. Food and Drug Administration (FDA) from November 10 to 14, 2025. Recently, the company received the FDA’s on-site inspection report, confirming that the inspection has concluded. The report indicates that the production line for pantoprazole sodium raw material at Chiral Drug Company meets FDA requirements in terms of quality management and compliance. This positive outcome will benefit the company’s future performance and enhance its competitiveness in international markets.

Aidi Pharmaceutical: Daclatasvir tablets approved for drug registration**

Aidi Pharmaceutical (688488) announced on March 15 that it received the drug registration certificate for Daclatasvir tablets, approved by the National Medical Products Administration on March 10. The approved indications include use in combination with other antiretroviral drugs for treating HIV-infected adults and children aged 12 and above.

(Source: Eastmoney Research Center)